DALLAS—Elara Caring, a provider of skilled home health, hospice, behavioral health and personal care services, announced that it has entered into an agreement for an investment from Ares’ Private Equity Group and DaVita.
Elara said the investment is intended to expand access to personalized, clinically advanced care at home for patients with complex and acute needs. The company added it will continue to operate as a wholly independent company led by CEO Ananth Mohan and the current management team. Following the closing, the parties will collaborate to help Elara expand access to care through new care models and clinical programs.
As a key focus of the investment, DaVita and Elara said they intend to co‑develop a kidney‑specific home‑based care model. This new model will build upon Elara’s existing clinical capabilities and apply DaVita’s advanced clinical insights to meet the needs of patients with kidney disease, seeking to reduce preventable hospitalizations and helping to lower the total cost of care.
“Too often, home-based care is introduced late in the care journey, significantly impacting outcomes and quality of life, especially with our vulnerable populations,” said Ananth Mohan, Elara Caring's CEO. “This collaboration reflects a shared belief that care should be timelier, more personalized and meet patients where they are most comfortable—at home. Together with Ares and DaVita, we have an extraordinary opportunity to improve the management of chronic conditions and deliver better results for patients and their loved ones as well as our healthcare system overall. We are thrilled to welcome them as partners.”
“Elara Caring is a leading home care platform defined by a commitment to quality and a patient-first culture,” said Kevin Cox, partner in Ares’ Private Equity Group. “We’re excited to partner with the Elara team and support their next phase of growth and innovation—expanding access, improving outcomes and delivering an outstanding experience for patients and team members.”
The closing of the transaction is subject to customary closing conditions, including receipt of regulatory approvals and is expected to occur later in 2026. The terms of the transaction were not disclosed.